Cite
HARVARD Citation
Wang, M. et al. (2021). Immune‐related adverse events of a PD‐L1 inhibitor plus chemotherapy versus a PD‐L1 inhibitor alone in first‐line treatment for advanced non–small cell lung cancer: A meta‐analysis of randomized control trials. Cancer. 127 (5), pp. 777-786. [Online].